Exagen's Q1 2026 earnings show record revenue of $17.3M, 12% YoY growth, and reaffirmed guidance of $70-$73M for the year.

Key Takeaways

• Revenue for Q1 2026 reached $17.3 million, marking a 12% year-over-year increase.
• Gross margin improved to 59%, with adjusted EBITDA loss reduced to $2.2 million, a 14% improvement compared to Q1 2025.
• Average Selling Price (ASP) expanded by 6%, reaching $444, driven by improved revenue cycle management.
• Test volume grew 10% year-over-year, with the company maintaining a steady quarterly run rate of mid-30,000 tests.
• Full-year 2026 revenue guidance reaffirmed at $70 to $73 million.

Financial Performance

Exagen Inc. kicked off 2026 with impressive financial results, showcasing a record revenue of $17.3 million for the first quarter. This figure represents a significant 12% increase from the same period last year. The company’s growth trajectory is indicative of its strategic focus on enhancing its product offerings and operational efficiencies.

Gross margin remained strong at 59%, reflecting ongoing advancements in cost management and operational execution. The adjusted EBITDA loss for the quarter was $2.2 million, which illustrates a 14% improvement compared to Q1 2025. This progress in profitability metrics reinforces the effectiveness of Exagen's strategic initiatives aimed at becoming a durable, value-compounding enterprise.

The rise in revenue was further supported by a 10% increase in test volume year-over-year, maintaining a stable quarterly run rate in the mid-30,000s. The company also reported a 6% increase in its average selling price (ASP), which reached $444 due to improved revenue cycle management and favorable collections timing. These metrics collectively highlight Exagen's ability to enhance both its top-line growth and profitability.

Strategic Initiatives

Exagen's strategy revolves around three core pillars: expanding product adoption, increasing ASP through disciplined revenue cycle execution, and delivering consistent innovation. In Q1 2026, the company saw a 15% increase in the number of ordering clinicians, indicating effective penetration into its target market. This uptick is critical as it reflects growing engagement and trust among healthcare providers.

The company is also focused on launching new products, with plans to introduce a standalone offering for Myositis in early 2027. This product is anticipated to meet a significant market need, as Myositis is often underdiagnosed due to inadequate testing. The launch aligns with the company’s mission to provide better diagnostic tools for complex autoimmune diseases, thereby improving patient outcomes.

Exagen’s commitment to innovation is further evidenced by its participation in Autoimmunity 2026, where it had nine abstracts accepted, including research related to Myositis. This visibility at key conferences helps establish Exagen as a thought leader in the autoimmune diagnostic space, promoting its brand and products to a wider audience.

Future Outlook

Looking ahead, Exagen remains optimistic about its growth trajectory. The company reaffirms its full-year 2026 revenue guidance of $70 to $73 million, based on expectations of high single-digit percentage volume growth and low single-digit percentage ASP growth. The management expressed confidence in sustaining this momentum, especially given the positive trends in ordering and test volume.

Management highlighted the importance of continued execution and operational discipline in achieving these goals. The company’s approach to enhancing its revenue cycle management and expanding its sales force is expected to yield positive results in the coming quarters. Additionally, the ongoing improvements in ASP and strong demand for its products position Exagen favorably in a growing market.

Exagen also noted that the autoimmune testing market is estimated to be over $2.2 billion, growing at about 5% annually. With just over 3% market share, the company recognizes significant opportunities to increase its footprint through improved service delivery and innovative solutions.

In terms of cash management, Exagen ended the quarter with nearly $22 million in cash, ahead of internal expectations. This solid financial position provides the company with the runway needed to support its growth initiatives and continue pursuing operational excellence.

Closing Assessment

Exagen Inc. has successfully set a strong foundation for 2026, demonstrating robust financial performance and strategic growth initiatives that are likely to solidify its position in the autoimmune diagnostics market. With a committed leadership team and a focus on innovation, the company is well-positioned to capitalize on emerging opportunities in the healthcare sector. Investors should remain optimistic as the company continues to execute its strategic plan while addressing the critical needs of autoimmune patients and clinicians.

This analysis is based on public earnings call materials and is not investment advice.